Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer

Julia Kallenbach; Golnaz Atri Roozbahani; Mehdi Heidari Horestani; Aria Baniahmad

doi:10.1186/s13578-022-00941-0

Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer

Cell Biosci. 2022 Dec 15;12(1):200. doi: 10.1186/s13578-022-00941-0.

Authors

Julia Kallenbach^#¹, Golnaz Atri Roozbahani^#¹, Mehdi Heidari Horestani^#¹, Aria Baniahmad²

Affiliations

¹ Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Am Klinikum 1, 07740, Jena, Germany.
² Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Am Klinikum 1, 07740, Jena, Germany. aria.baniahmad@med.uni-jena.de.

^# Contributed equally.

Abstract

Background: Prostate cancer (PCa) is an age-related malignancy in men with a high incidence rate. PCa treatments face many obstacles due to cancer cell resistance and many bypassing mechanisms to escape therapy. According to the intricacy of PCa, many standard therapies are being used depending on PCa stages including radical prostatectomy, radiation therapy, androgen receptor (AR) targeted therapy (androgen deprivation therapy, supraphysiological androgen, and AR antagonists) and chemotherapy. Most of the aforementioned therapies have been implicated to induce cellular senescence. Cellular senescence is defined as a stable cell cycle arrest in the G1 phase and is one of the mechanisms that prevent cancer proliferation.

Results: In this review, we provide and analyze different mechanisms of therapy-induced senescence (TIS) in PCa and their effects on the tumor. Interestingly, it seems that different molecular pathways are used by cancer cells for TIS. Understanding the complexity and underlying mechanisms of cellular senescence is very critical due to its role in tumorigenesis. The most prevalent analyzed pathways in PCa as TIS are the p53/p21^WAF1/CIP1, the p15^INK4B/p16^INK4A/pRb/E2F/Cyclin D, the ROS/ERK, p27^Kip1/CDK/pRb, and the p27^Kip1/Skp2/C/EBP β signaling. Despite growth inhibition, senescent cells are highly metabolically active. In addition, their secretome, which is termed senescence-associated secretory phenotype (SASP), affects within the tumor microenvironment neighboring non-tumor and tumor cells and thereby may regulate the growth of tumors. Induction of cancer cell senescence is therefore a double-edged sword that can lead to reduced or enhanced tumor growth.

Conclusion: Thus, dependent on the type of senescence inducer and the specific senescence-induced cellular pathway, it is useful to develop pathway-specific senolytic compounds to specifically targeting senescent cells in order to evict senescent cells and thereby to reduce SASP side effects.

Keywords: Androgen receptor; Cancer cell senescence; Chemotherapy; Exosome; Prostate cancer; Radiotherapy; Senescence-associated secretory phenotype.

Publication types

Review